Fluticasone propionate/salmeterol - GlaxoSmithKline

Drug Profile

Fluticasone propionate/salmeterol - GlaxoSmithKline

Alternative Names: Adoair Aerosol; Adoair Diskus; Advair Diskus; Advair HFA; Anasma Accuhaler; Atmadisc; Fluticasone propionate/salmeterol; Inaladuo; Plusvent Accuhaler; salmeterol xinafoate/fluticasone propionate; Seretide; Seretide Accuhaler; Seretide Diskus; Seretide Evohaler; Seretide MDI; Viani

Latest Information Update: 28 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glaxo Wellcome SA; GlaxoSmithKline
  • Developer GlaxoSmithKline
  • Class Androstadienes; Antiallergics; Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease
  • Discontinued Rhinitis

Most Recent Events

  • 20 Dec 2017 GlaxoSmithKline received label changes approval to remove the boxed warning for fluticasone propionate/ salmeterol
  • 01 Nov 2016 GlaxoSmithKline completes a phase III trial in Asthma (In Children, In adults, In adolescents) in USA, Argentina, Brazil, Chile, Czech Republic, Germany, South Korea, Mexico, Netherlands, Romania, Russia and Spain (Inhalation, Powder) (NCT02301975)
  • 03 Sep 2016 Additional adverse events data from phase IV trials (AUSTRI and VESTRI) in Asthma presented at the 26th Annual Congress of the European Respiratory Society (ERS - 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top